|Min SIP Amount||₹500|
|NAV||₹19.67 (11 Jun 2021)|
|Fund Started||27 Feb 2019|
|Fund Size||₹76 Cr|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||10.7%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||10.7%|
|Divi's Laboratories Ltd.||Healthcare||Equity||9.8%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||6.5%|
|Apollo Hospitals Enterprise Ltd.||Healthcare||Equity||4.8%|
|Ipca Laboratories Ltd.||Healthcare||Equity||4.4%|
|JB Chemicals & Pharmaceuticals Ltd.||Healthcare||Equity||2.8%|
|Laurus Labs Ltd.||Healthcare||Equity||2.8%|
IDBI Healthcare Fund Direct Growth is a Equity Mutual Fund Scheme launched by IDBI Mutual Fund. This scheme was made available to investors on 27 Feb 2019. Uma Venkatraman is the Current Fund Manager of IDBI Healthcare Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹76 Cr and the Latest NAV as of 11 Jun 2021 is ₹19.67.
The IDBI Healthcare Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 12 months.
The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors.